Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C27H36F2O3 and a molecular weight of approximately 446.6 g/mol[1][2][3]. It features a steroidal cyclopenta[a]phenanthrene core structure substituted with a 3',5'-difluorobenzyl ether side chain and hydroxyl/methyl groups at key positions[1][2]. The compound is listed in chemical databases as an experimental or research molecule; there is no evidence it has been approved for clinical use or assigned to any marketed drug product[3]. Its mechanism of action and pharmacological profile are not described in public sources; however—based on its structure—it may be related to steroid hormone analogs or modulators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-difluorobenzyl)oxy]ethyl}-17-hydroxy-10-methylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one.